Ambulatory Fluoroquinolone Use in the United States, 2014 to 2019 by Umarje, Siddhi Pramod
 i 
AMBULATORY FLUOROQUINOLONE USE IN THE UNITED STATES, 2014 to 2019 
by 





A thesis submitted to Johns Hopkins University in conformity with the requirements 



















Importance.  Fluoroquinolones have been subject to increasing safety concerns and regulatory 
advisories. In the face of emerging risks, some evidence suggest they remain widely prescribed 
in ambulatory settings, and the impact of regulatory risk communications remains unclear. 
Objectives. i) To quantify and characterize ambulatory fluoroquinolone utilization in the United 
States between January 2014 and December 2019, and ii) to evaluate the effect of 2016 U.S. 
Food and Drug Administration (FDA) advisories on fluoroquinolone use. 
Design, participants and outcomes.  We used IQVIA’s National Disease and Therapeutic 
Index (NDTI) to quantify quarterly and annual outpatient visits where a fluoroquinolone was 
used among individuals age > 20 years. We used descriptive statistics to report the utilization 
trends from 2014 to 2019, stratified by fluoroquinolone type, diagnoses and prescriber 
characteristics; and segmented-regression analysis to quantify the impact of 2016 FDA risk 
communications on fluoroquinolone use.  
Results. Between 2014 to 2019, fluoroquinolone use decreased by 27.8%. Ciprofloxacin 
accounted for highest number of treatment visits (58.39 %), followed by levofloxacin (34.14 %). 
Over the six-year period, utilization decreased among non-surgeons by 37.3%; whereas, use 
increased by 25.6% among surgeons.  The magnitude of fluoroquinolone use varied remarkably 
by clinical indication and provider age. For example, use declined by 45.9% for respiratory 
conditions vs 28.5% for urogenital conditions vs 20.4% for gastrointestinal conditions. 
Fluoroquinolone use declined by 73.9% among providers < 44 years-old compared to a decline 
that ranged from 1- 40% among those > 45 years-old. Prior to the 2016 regulatory advisories, 
there were ~ 4.8 million fluoroquinolone treatment visits per quarter. In the post-advisory period, 
there was a statistically significant level drop by 641,035 visits (p-value = 0.000, 95% C= -
937368, -344702) and a statistically significant difference in pre and post utilization trends by 
~45k visits (p-value = 0.036 -85956, -3122.345) 
 iii 
Conclusions and Relevance.  Large reductions in ambulatory fluoroquinolone use in the 
United States have coincided with increasing evidence and FDA risk communications regarding 
of their potential risks. Despite this, changes in fluoroquinolone use have varied based on 
patient and provider characteristics, suggesting heterogeneous effects of emerging risks on 
clinical practice.  
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The first fluoroquinolone, Norfloxacin, was approved by the U.S. Food and Drug Administration 
(FDA) in 1986 for treating genitourinary infections.  Since then, six additional fluoroquinolone 
products (ciprofloxacin, ofloxacin, gemifloxacin, levofloxacin, moxifloxacin and delafloxacin) 
have been approved by the FDA.1  These products are widely prescribed and are ranked as the 
fourth most commonly prescribed antibiotic class in the United States, 2 in part because of their 
wide spectrum of activity, excellent bioavailability, extensive penetration in tissue and successful 
microbiological outcomes.3 
Despite their clinical value, fluoroquinolones are associated with a host of potential adverse 
effects.  Some of these, such as diarrhea, nausea, and headaches, have been well described in 
the drug label since their earliest FDA approval. However, other more severe safety concerns 
have been increasingly well characterized over the past few decades. For example, 
fluoroquinolone-induced achilles tendinopathy, first reported in New Zealand in 1983, has since 
been well described in numerous observational studies.4,5 Meta-analysis of studies on 
fluoroquinolone associated tendinopathies suggests that fluoroquinolone users have a two and 
a half times higher risk of achilles tendon rupture, fourfold higher risk of achilles tendinitis, and 
two-fold higher risk of any tendon disorder, as compared non-users, a risk that is especially 
elevated among elderly individuals. 6 Similarly, fluoroquinolone users are twice likely to suffer 
from peripheral neuropathy than non-users.7 The risk is dose-dependent and increases by 3% 
with every additional day of exposure.8 Fluoroquinolones are also known to induce mental 
disturbances such as psychoses, disorientation, agitation, nervousness, impaired memory and 
delirium. 9,10 Case reports and observational studies also suggest a dose - duration dependent 
risk of aortic aneurysm, dissection, tears and ruptures among fluoroquinolone users. 11 -14. 
 2 
Increasing discovery of side effects has led to multiple FDA safety alerts and advisories for 
these products (Appendix 1). In July 2008, FDA released a boxed warning to address the 
specific risk of tendinitis and tendon rupture among fluoroquinolone users, 15 followed by 
another warning in August 2013 addressing the risk of irreversible peripheral neuropathy16. In 
May 2016, FDA issued a safety alert cautioning the prescribers about potentially disabling side-
effects of fluoroquinolones affecting two or more organ systems and recommended to avoid its 
use in acute uncomplicated infections. Consequently, in July 2016, FDA approved a class-wide 
label change for addressing risk of central nervous system side-effects and peripheral 
neuropathy and limiting use of fluoroquinolones in acute uncomplicated infections. 17 More 
recently still, in 2018, FDA noted fluoroquinolones’ associated risk of severe hypoglycemia, 
mental side-effects such as disorientation and impaired memory and risk of aortic aneurysm, 
dissection, tear and rupture potentially causing fatal bleeding.18  
In face of emerging safety concerns over the past decade, fluoroquinolone utilization has been 
consistently high.19 For example, fluoroquinolone prescribing in the United States rose 3-fold 
from 1995 to 2002 and was the most commonly prescribed antibiotic across all types of care -
settings in 2009. 20,21 In 2016, fluoroquinolone antibiotics were the 4th most commonly 
prescribed class of medicine in outpatient setting of United States. 2 
To our knowledge, fluoroquinolone use in outpatient setting has not been well characterized. In 
addition, it is unclear whether fluoroquinolone use differs by physician and patient 
characteristics. Moreover, we do not know the impact of FDA advisories on fluoroquinolone use 
in outpatient care settings of United States.  
Thus, through this study, we sought to characterize the impact of FDA advisories on changes in 
outpatient fluoroquinolone use and identify characteristics that may inform such change. We 
hypothesized a decline in fluoroquinolone use over time. Further, we hypothesized that FDA risk 
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communications may have contributed to such declines by raising awareness among 
prescribers and patients regarding potential serious adverse effects associated with 



















We used IQVIA’s National Disease and Therapeutic Index (NDTI) to obtain annual and quarterly 
data on fluoroquinolone use from January 2014 through December 2019. NDTI sample is an 
office-based panel of physicians providing care in both community and academic settings in the 
continental United States and has been used previously to examine drug utilization.22-24  The 
universe of NDTI physicians is obtained from American Medical Association Masterfile and 
American Osteopathic Association. Approximately 4000 participating physicians report on all 
patient contacts occurring during two consecutive workdays in each calendar quarter using a 
web-based form for each patient-encounter. The physicians report patient’s demographic 
details, diagnoses and treatments for every visit. Each therapy record is linked to a 6-digit 
taxonomy code similar to the World Health Organization’s International Classification of 
Disease, ninth revision (ICD-9). Using sample weights, nationally representative estimates are 
obtained for ~534,000 physicians all over the US.  
Products examined 
We used FDA.gov to identify the approved fluoroquinolone products marketed in the United 
States between 2014 to 2019.1 We excluded topical fluoroquinolone products such as optic and 
otic solutions from our analysis since safety concerns regarding fluoroquinolones have been 
limited to oral formulations. We included all products licensed for marketing in the United States 
during the study period, including ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, 





Our primary unit of analysis was treatment visits, which is defined as an ambulatory visit where 
an individual was diagnosed with a condition and treated with a pharmacologic product. Thus, 
every fluoroquinolone treatment visit account for an ambulatory visit where fluoroquinolone was 
either initiated or continued.  
Descriptive analysis 
Using annual and quarterly (Q) estimates from January 2014 to December 2019, we used 
descriptive statistics to analyze the trends of fluoroquinolone utilization. We limited our analysis 
to adults aged 20 years and older and stratified the utilization by key patient (age, sex, 
diagnosis) and prescriber (specialty, age) characteristics.  We used mutually exclusive 
diagnosis categories based on major organ systems such as urogenital system, respiratory 
system, gastrointestinal system, skin/musculoskeletal system, blood/lymphatic system/cancer, 
and otolaryngology. We grouped the providers into 2 broad categories, non-surgeons and 
surgeons (Appendix 2).  Non-surgeons consisted of primary care physicians, internal medicine 
doctors and non-surgeons.  For ease of reporting the results, we grouped the fluoroquinolone 
products in 3 broad categories, ciprofloxacin, levofloxacin and ‘other fluoroquinolones.’ The 
category ‘other fluoroquinolones’ consists of moxifloxacin, ofloxacin, delafloxacin and 
gemifloxacin. We also examined the fraction of overall treatment visits for urogenital, 
respiratory, and gastrointestinal conditions that were accounted for by fluoroquinolone product 
and stratified these findings by prescriber specialty. For all yearly estimates, we derived 95% 
confidence intervals using information about standard errors accompanying the survey sampling 
methodology (Appendix 3). 
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Impact of FDA advisories on fluoroquinolone use 
Using an interrupted time-series analysis we examined the effect of 2016 FDA advisories on 
trends in fluoroquinolone use from January 2014 to December 2019. Prior to this analysis we , 
identified the ideal inflection points in our segmented analysis by i) visually inspecting the 
quarterly trends of fluoroquinolone use while superimposing the FDA advisories of interest on 
order to examine quarterly trends in fluoroquinolone use; and ii) using Joinpoint regression, a 
permutation method developed by the National Cancer Institute, to test for possible inflection 
points in time-series data without defining interventions a priori.25,26 Visual inspection of the data 
and Joinpoint regression suggested  significant inflection points at the second and third quarter 
of 2016, respectively. These inflection points closely coincided with the FDA’s May 2016 and 
July 2016 advisories. (Appendix 4)  
Considering the lag time and overlapping effects of May 2016 and July 2016 FDA advisories, 
we examined their combined effect by collapsing the 2016 Q2 and 2016 Q3 into one time point 
labelled as ‘advisory period’. Thus, our study period consists of i) pre-advisory period of 9 
quarters, from 2014 Q1 to 2016 Q1; ii) advisory period of 2 quarters, 2016 Q2 and 2016 Q3; iii) 
post-advisory period of 13 quarters, from 2016 Q4 to 2019 Q4.  
We modeled the data using a linear trend model in which outcome variable was defined as 
average number of treatment visits per quarter. The regression included a linear trend, a 
dummy variable for the post-advisory period, and an interaction term. Thus, we could directly 
estimate the immediate change (level) of fluoroquinolone use after the advisories were issued 
and compare the pre-advisory and post-advisory trends (slope) in fluoroquinolone use. The 
model’s goodness-of-fit was examined by the value of R-square statistic (0.89). This was further 
supported by plots of residual versus fitted values, and histogram of residuals suggesting 
random variance in the data. We examined for autocorrelation and seasonal trends using 
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correlograms derived by Bartlett’s formula and lagged correlation, respectively. We did not 
identify statistically significant autocorrelation or seasonal trends in the data.  
The results of segmented regression analysis were reported as i) average number of treatment 
visits per quarter in the pre-advisory period (pre-alert utilization trend); ii) immediate impact of 
advisories on utilization (level change); iii) average number of treatment visits per quarter in 
post-advisory period (post-alert utilization trend); iv) the difference in pre and post utilization 
trends. The statistical significance was determined by 95% confidence intervals and p-value.  
Descriptive analysis was performed using Microsoft Excel (version 16.34) and segmented 
regression analysis was performed using STATA software (version 15). This study was exempt 













Overall utilization of fluoroquinolone antibiotics, 2014 to 2019 
Between January 2014 and December 2019, fluoroquinolone use declined by nearly one third 
(27.8%), from approximately 19.1 million treatment visits in 2014 to 13.8 million treatment visits 
in 2019. Ciprofloxacin and Levofloxacin were the top-selling fluoroquinolone products 
accounting for more than 90% of the market share during this period. The remaining 10% 
treatment visits were accounted for other types of fluoroquinolones (moxifloxacin, ofloxacin, 
delafloxacin, and gemifloxacin). By the end of 2019, there was a 40.9% decline in Levofloxacin 
use, 26.9% decline in Ciprofloxacin use, and 59.3% increase in use of other types of 
fluoroquinolones (Table 1, Figure1). The quarterly trends of fluoroquinolone utilization showed a 
30.7% decline over 6 years, with largest decline (14.19%) observed in 2016 Q2. (Figure 2)  
Trends in fluoroquinolone use by prescriber specialty, 2014 to 2019 
Over the period examined, approximately 13.3 million (81%) treatment visits/year were 
accounted for by non-surgeons whereas approximately 3 million (19%) treatment visits/year 
were accounted for by surgeons. By the end of 2019, fluoroquinolone use among non-surgeons 
declined by 37.3%, from 16.2 million treatment visits in 2014 to 10.1 million treatment visits in 
2019. Among surgeons, fluoroquinolone use increased by 25.6%, from 2.8 million treatment 
visits in 2014 to 3.6 million treatment visits in 2019. (Table 1) 
Trends in fluoroquinolone use by diagnosis, 2014 to 2019 
The highest number of treatment visits were accounted for by urogenital conditions, with an 
average of 6.9 million (43%) treatment visits/year. The second highest use was accounted for 
by respiratory conditions, with an average of 4.9 million (30.2%) treatment visits/year. 
Gastrointestinal conditions accounted for approximately 1.5 million (9.6%) treatment visits/year. 
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Conditions affecting the skin or musculoskeletal system, blood, lymphatic systems, and cancers 
accounted for fewer than 10% of all fluoroquinolone treatment visits per year. By the end of 
2019, fluoroquinolone use for respiratory conditions declined by 46%, from 6.3 million treatment 
visits in 2014 to 3.4 million treatment visits in 2019. Similarly, use declined by 28.5% for 
urogenital conditions and 20.3% for gastrointestinal conditions. (Table1, Figure 3) 
Proportion use of fluoroquinolones over all treatment visits, 2014 to 2019 
Among non-surgeons, although the overall number of treatment visits for urogenital conditions 
increased by 6.9% (3 million in 2014 to 3.2 million in 2019), the treatment visits accounted for by 
fluoroquinolone products declined by 83.8% (6.7 million in 2014 to 1.1 million in 2019); whereas, 
among surgeons, the overall treatment visits for urogenital conditions decreased by 6.9% and 
the fraction accounted for by fluoroquinolone products increased by 12.5 %, from 1.1 million in 
2014 to 1.2 million in 2019.  
From 2014 to 2019 the overall number of treatment visits for respiratory conditions among both 
specialties of care showed moderate decline by ~7%; however, the fraction of treatment visits 
accounted for by fluoroquinolones showed large declines by 45.7% among non-surgeons and 
59.5% among surgeons.  
Over the study period, fraction of treatment visits for gastrointestinal conditions accounted for by 
fluoroquinolone products decreased by 26% among non-surgeons and increased by 2.8% 
among surgeons. (Table 2 and Table 3) 
Trends in fluoroquinolone use by prescriber age, 2014 to 2019 
Between 2014 to 2019, on an average 134,000 (8%) treatment visits/year were accounted for 
by physicians ≤44 years; whereas, 15 million (92%) treatment visits/year were accounted for by 
physicians > 45 years old. Fluoroquinolone use was highest among physicians 55-64 years, 
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accounting for approximately 4.3 million (40%) of treatment visits/year. Over the period 
examined, larger declines in use were observed among younger physicians. For example, from 
2014 to 2019 the number of fluoroquinolone treatment visits among physicians ≤ 44 years 
declined by 74% (from 2.1 million in 2014 to 549,000 in 2019) as compared to 40.3% (from 4.9 
million in 2014 to 2.9 million in 2019) decline among those 45-54 years old, 22.3% (from 7.5 
million to 5.8 million) decline among those 55-64 years old and 1% (from 4.46 million to 4.42 
million) decline among those >65 years old. (Table 1) 
Impact of 2016 FDA advisories on fluoroquinolone use 
In the pre-advisory period (2014 Q1 – 2016 Q1), fluoroquinolone use was approximately 4.8 
million treatment visits/quarter with a statistically non-significant decline of 9274 treatment visits/ 
quarter (p-value = 0.51, 95% CI = -38184, 19637). Immediately after the 2016 FDA advisories 
(2016 Q2 & 2016 Q3), there was a statistically significant decline in fluoroquinolone use by 
641,035 treatment visits (p-value = 0.000, -937368, -344702). In the post-advisory period (2016 
Q4 - 2019 Q4) fluoroquinolone use was approximately 4.1 million treatment visits/quarter. The 
pre-advisory and post-advisory trends in fluoroquinolone use showed a statistically significant 









While declines in fluoroquinolone use preceded the 2016 FDA regulatory advisories, these risk 
communications were associated with further statistically significant decline in use. Over the 
study period, fluoroquinolone use declined by more than 25 %; characterized by highest decline 
for respiratory conditions. Changes in use varied remarkably by provider’s age, with younger 
physicians much more likely to decrease fluoroquinolone use than their older counterparts.  
These findings are important because they suggest the underlying differences among 
prescribers which affect the trends in utilization of a drug that is associated with multiple safety 
concerns.  
Our study reports a sizeable decline (~28%) in fluoroquinolone use and statistically significant 
association of 2016 FDA advisories with further declines in fluoroquinolone use. These findings 
are supported by another study evaluating the impact of July 2016 FDA alert on in-patient 
utilization of fluoroquinolones across 29 southeastern hospitals of the United States, from 2013 
to 2017. The authors reported ~25 % decline in fluoroquinolone use in the pre-advisory period 
from January 2013 to July 2016, a statistically significant decline by 7.6% immediately following 
the alert in August 2016, followed by statistically non-significant decline by 0.9% per month in 
the post-alert phase from August 2016 to December 2017. 27 Other similar studies have 
reported small and statistically non-significant decelerations in fluoroquinolone use after FDA’s 
July 2016 alert.28,29 The immediate and long-term declines observed in this study can be 
explained by the overlapping effects of adjacent FDA alerts, considering the lead and lag time 
for each alert to take into effect. Moreover, in 2018, FDA issued two other safety alerts for 
fluoroquinolone antibiotics highlighting the serious risks such as hypoglycemia, mental 
disturbances, and aortic aneurysm tears or rupture. These alerts could probably have an 
additional effect on the declining utilization trends. Furthermore, the declines in fluoroquinolone 
use could be attributed to factors such as the provider and patient response to emerging safety 
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information, antibiotic stewardship programs (ASPs) and educational activities aimed at 
clinicians and patients. 30-32 In the recent past, ASPs have been a source of focused effort to 
improve the patient-outcomes and optimize antibiotic use. ASP associated reduction in 
unnecessary prescribing and improved selection of antibiotics has been well-discussed in 
previous studies.32 For example, Lin et al reported that a multi-modal ASP implemented in 
outpatient clinic, emergency care and urgent emergency care center of a hospital in Texas led 
to 34% decline in fluoroquinolones use and the proportion of inappropriate use of 
fluoroquinolones decreased from 53% in October 2016 to 34% in October 2018 30. Other factors 
such as secular trends in infection rates, changes in clinical guidelines, and new antibiotic 
products being brought to market may also play a role in the changing utilization trends. 
In this study, the largest proportion for fluoroquinolone treatment visits were accounted for by 
urogenital conditions. This finding is strongly supported by a study reported by Kabbani and 
colleagues, who examined the outpatient fluoroquinolone use in the United States from 2013 to 
2014. The authors reported that, fluoroquinolone use was highest for urogenital conditions. 
Furthermore, ~40% of fluoroquinolone use for urogenital conditions was for uncomplicated 
urinary tract infections suggesting a high proportion of use contradictory to FDA 
recommendations. Therefore, the high utilization of fluoroquinolones for urogenital conditions in 
our study could potentially reflect the inappropriate use of fluoroquinolones. However, it is 
difficult to determine the rationality of fluoroquinolone use as it is beyond the scope of this 
study.33 Interestingly, the large decline in fluoroquinolone use for respiratory conditions that we 
observed may be attributable to FDA advisories. The May 2016 and July 2016 alerts directly 
recommend avoiding fluoroquinolone use for acute bacterial sinusitis and bronchitis.17 Moreover, 
ASPs are reported to have significant effect on reducing fluoroquinolone use for respiratory 
conditions. For example, antibiotic stewardship program conducted in a hospital in Texas 
significantly reduced the fluoroquinolone use by 58% for cystitis and 33% for bronchitis.34  
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Approximately three-fifths of fluoroquinolone use was accounted for by non-surgeons such as 
primary care physicians, internal medicine doctors and medicine specialties. This finding can be 
related to the high number of infections treated by primary care doctors or medicine specialists 
in outpatient settings. This finding can be supported by the 2017 CDC report on outpatient 
antibiotic use that suggests 1.5 to 3 times higher prescribing of antibiotics by medicine doctors 
as compared to surgeons.35 Moreover, antibiotic-decision-making may be perceived as a non-
surgical intervention that is often delegated to internal medicine doctors or infection specialists, 
thus, increasing the probability of non-surgeons to prescribe antibiotics in surgery patients.36  
By the end of 2019, fluoroquinolone use declined among non-surgeons by 37%; whereas, it 
increased by 26% among surgeons. This finding could be explained by the underlying 
differences in clinical practice and effects of evidence on prescribing behaviors. For example, 
summary of Canadian Medical Associations’ Physician Resource Questionnaire suggests that 
surgical specialists are less likely (32%) to refer online clinical practice guidelines as compared 
to medicine practitioners (~40%).37  This could possibly lead to differential dissemination of 
regulatory advisories and clinical updates among prescriber specialties.  
Previous studies strongly support the relationship between physician’s age, years of practice 
and declining quality of clinical care.38-39 For example, a systematic review determining the 
relationship between clinical experience and quality of health care reported that, 52% of 
reviewed studies show declining performance and lower quality of care with increasing years in 
physician’s practice. Physicians less than 40 years old are more likely have better knowledge 
about value of therapies and clinical updates; whereas, older physicians have less factual 
knowledge and seem less likely to be receptive to evidence-based practice guidelines.40 
Personal digital assistants which provide easy access to internet and clinical updates are used 
1.5 to 2 times higher among younger physicians than older counterparts and physicians using 
internet have higher impact of literature evidence on their clinical practice.39-40 Another study 
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reports that, more than 50% of younger physicians as compared to less than 25% of older 
physicians refer to online clinical practice guidelines.37 These findings corroborate and explain 

















STRENGTHS AND LIMITATIONS 
We have exclusively examined outpatient fluoroquinolone utilization for a period of 6 years. To 
our knowledge, no previous study has characterized fluoroquinolone use by patient and 
prescriber characteristics. Moreover, this study statistically examines the association of two 
adjacent FDA advisories issued in 2016 on the changing trends in fluoroquinolone use.  
Although our study has many strengths, it has several limitations. For example, the NDTI 
dataset is a survey weighted data with inherent sampling errors. Also, this data does not include 
approximately 100,000 physicians from specialties such as critical care medicine, preventive 
medicine and residency programs. Therefore, fluoroquinolones utilization among these 
specialties is not known. The FDA alerts are in adjacent quarters and therefore the lag in time-
to-effect makes it difficult to know the impact of each alert individually. The impact of other 
factors such as secular trends in infection rates, changes in clinical guidelines, and on-going 
antibiotic stewardships programs on utilization of fluoroquinolones is not known. Also, data 
describing use of other antibiotic classes was not available. Therefore, we could not compare 
the utilization trends of fluoroquinolone antibiotics with other antibiotics which further limited our 
scope to assess if the observed decline in fluoroquinolone use was associated with an 








In conclusion, fluoroquinolone use among adults in ambulatory care settings has declined 
remarkably over 6 years. The FDA advisories released in May 2016 and July 2016 had 
statistically significant association with decline in fluoroquinolone use. However, despite the 
decrease, the volume of prescribing continues to be high, raising concerns regarding the 
potential for continued overuse of these products in settings where they may have an 
unfavorable risk/benefit balance. The dissimilarities in fluoroquinolone utilization by prescriber 
characteristics suggests underlying differences in attitudes, knowledge and prescribing 
behavior. Identifying and targeting specific segments of prescribers may further help to reduce 
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Use is measured in thousands. Source data is obtained from IQVIA National Disease and Therapeutic Index.  























Table 2: Proportion of fluoroquinolone treatment visits over all treatment visits among 
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Urogenital conditions 







































Proportion use (%) 21.9 22.9 20.8 17.1 15.9 3.3 -84.9 
Respiratory conditions 







































Proportion use (%) 8.5 
 
9.1 7.9 6.3 6.1 4.9 -42.3 
Gastrointestinal conditions 



































Proportion use (%) 3.5 3.8 3.0 3.5 3.3 2.6 -25.7 
FQ = Fluoroquinolone antibiotics 
All counts are in thousands. 
Proportion use = FQ treatment visits/All treatment visits *100 





























































Proportion use (%) 6.4 5.6 6.2 5.6 6.3 7.2 12.5 
Respiratory 
































Proportion use (%) 5.2 6.2 2.7 3.2 3.2 2.3 -55.7 
Gastrointestinal 

































Proportion use (%) 3.6 4.5 3.2 3.9 3.7 3.7 2.8 
FQ = Fluoroquinolone antibiotics 
All counts are in thousands. 
Proportion use = FQ treatment visits/All treatment visits *100 




Table 4: Impact of 2016 FDA advisories on fluoroquinolone use 
 
Trends in fluoroquinolone use  Treatment visits  p-value (95% CI) 
Pre-alert period (2014 Q1 – 2016 Q1) 4780566 - 
Pre-alert change per quarter -9273 0.51 (-38184, 19637) 
Post-alert period (2016 Q4 – 2019 Q4) 4094993 - 
Immediate change (2016 Q4) -641035 0.000 (-937368, -344702) 
Before-after change in trend  -44539 0.036 (-85956, -3122.345) 

































Figure 2: Per-quarter utilization of fluoroquinolone antibiotics 
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Safety alert: Avoid use 
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Date Type of Alert Description 
July 2008 Black Box Warning Increased risk of tendinitis and tendon rupture. 
March 2011 Label change 
Dear Healthcare Provider Letter 
Potential for myasthenia gravis exacerbation. 
August 2013 Drug Safety Communication Risk of peripheral neuropathy. 
May 2016 Drug Safety Communication  Avoid use in uncomplicated acute sinusitis, 
acute exacerbations of chronic bronchitis and 
uncomplicated urinary tract infections.  
July 2016 Label Change 
 
Strengthening of 2008 boxed warning. Addition 
of information on risk of peripheral neuropathy 
and mental disturbances in boxed warming.  
Class-wide change in drug label: Indication of 
use modified as per May 2016 alert.  
July 2018 Drug Safety Communication  Risk of serious hypoglycemia which can lead to 
coma. 
Risk of mental health side effects - disturbance 
in attention, nervousness, memory impairment 
and delirium. 
Dec 2018 Drug Safety Communication  Systemic fluoroquinolones can double risk of 















Categorization of prescribers as per the specialty of care provided. 
 
Prescriber Category Specialties 
 
Medicine 
Emergency Medicine, Family Practitioner, General 
Practitioner, Geriatrics, Internal Medicine, Osteopathic, 
Neurology, Dermatology, Podiatry, Psychiatry, and Internal 
Medicine Subspecialties (Allergy, Cardiology, Endocrinology, 
Gastroenterology, Hematology, Nephrology, Oncology, 
Pulmonary, Rheumatology) 
Surgery Colon and Rectal Surgery, General Surgery, Orthopedic 































2017 NDTI 95%, 90% and 80% precision estimates   
   
Projected Count Confidence Intervals  
(000) 95 %  90%  80%  
2,000,000 2.09 1.76 1.37 
1,000,000 2.67 2.24 1.75 
900,000 2.77 2.32 1.81 
800,000 2.89 2.42 1.89 
700,000 3.02 2.54 1.98 
600,000 3.19 2.68 2.09 
500,000 3.40 2.86 2.22 
400,000 3.68 3.09 2.41 
300,000 4.07 3.41 2.66 
200,000 4.69 3.94 3.07 
100,000 5.98 5.02 3.91 
90,000 6.20 5.21 4.06 
80,000 6.46 5.42 4.23 
70,000 6.77 5.68 4.43 
60,000 7.15 6.00 4.67 
50,000 7.62 6.39 4.98 
40,000 8.24 6.91 5.39 
30,000 9.11 7.65 5.96 
20,000 10.50 8.81 6.87 
10,000 13.39 11.23 8.75 
9,000 13.89 11.66 9.08 
8,000 14.47 12.15 9.46 
7,000 15.17 12.73 9.92 
6,000 16.01 13.43 10.47 
5,000 17.06 14.32 11.16 
4,000 18.45 15.48 12.06 
3,000 20.40 17.12 13.34 
2,000 23.52 19.74 15.38 
1,000 29.97 25.16 19.60 
900 31.10 26.10 20.34 
800 32.41 27.20 21.19 
700 33.96 28.50 22.21 
600 35.84 30.08 23.44 
500 38.21 32.07 24.98 
400 41.31 34.67 27.02 
300 45.69 38.35 29.88 
200 52.66 44.20 34.44 




































For X-axis:  
1 - 4 ≙ 2014 Q1 to 2014 Q4 
5 - 8 ≙ 2015 Q1 to 2015 Q4 
9 - 12 ≙ 2016 Q1 to 2016 Q4 
13 - 16 ≙ 2017 Q1 to 2017 Q4 
17 - 20 ≙ 2018 Q1 to 2018 Q4 
21 - 24 ≙ 2019 Q1 to 2019 Q4 
*Indicates that the slope is significantly different from zero at the alpha=0.05 level                   
*The dotted points show calendar quarters  
*The solid line is fitted joinpoint time series.  
 




Dr. Alexander is past Chair of FDA’s Peripheral and Central Nervous System Advisory 
Committee; has served as a paid advisor to IQVIA; is a co-founding Principal and equity holder in 
Monument Analytics, a health care consultancy whose clients include the life sciences industry 
as well as plaintiffs in opioid litigation; and is a member of OptumRx’s National P&T Committee.  
This arrangement has been reviewed and approved by Johns Hopkins University in accordance 
with its conflict of interest policies. Dr. Cohen is a paid consultant to Monument Analytics. This 
arrangement has been reviewed and approved by Johns Hopkins University in accordance with 





















1. US Food and Drug Administration FDA-Approved Drugs. Available from: 
https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed November 23, 2019. 
2. Centers for Disease Control and Prevention. Outpatient antibiotic prescriptions- United 
States 2016, Annual report 2016. Available from: https://www.cdc.gov/antibiotic-
use/community/programs-measurement/state-local-activities/outpatient-antibiotic-
prescriptions-US-2016.html. Accessed November 23, 2019. 
3. Oliphant C, Green G. Quinolones: A comprehensive review. Am Fam Physician. 2002; 
65(3):455-465.   
4. Kim GK. The Risk of Fluoroquinolone-induced Tendinopathy and Tendon Rupture: What 
Does The Clinician Need To Know?. J Clin Aesthet Dermatol. 2010;3(4):49–54. 
5. Khaliq Y, Zhanel GG. Fluoroquinolone-Associated Tendinopathy: A Critical Review of 
the Literature. Clinical Infectious Diseases.2003;36(11):1404–1410.  
6. Alves C, Mendes D, Marques FB. Fluoroquinolones and the risk of tendon injury: a 
systematic review and meta-analysis. Eur J Clin Pharmacol. 2019 Oct;75(10):1431-1443 
7. Etminam M, Brophy JM, Samil A. Oral fluoroquinolone use and risk of peripheral 
neuropathy: a pharmacoepidemiologic study. Neurology. 2014; 30;83(14):1261-1263 
8. Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X. Association 
between peropheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-
clavulanate therapy. JAMA Neurology. 2019;76(7):827-833. 
9. Sahoo S, Aneja J, Basu D. Recurrent mania consequent to quinolones exposure: A case 
report and review of literature. J Family Med Prim Care. 2016;5(1):163–165. 
doi:10.4103/2249-4863.184654 
10. Moorthy N, Raghavendra N, Venkatarathnamma PN. Levofloxacin-induced acute 
psychosis. Indian J Psychiatry. 2008;50(1):57–58. 
 
 30 
11. Lee C, Lee MG, Chen Y, et al. Risk of Aortic Dissection and Aortic Aneurysm in Patients 
Taking Oral Fluoroquinolone. JAMA Intern Med. 2015;175(11):1839–1847.  
12. Pasternak B, Inghammar M, Svanström. Fluoroquinolone use and risk of aortic 
aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:K678 
13. Singh S, Nautiyal A. Aortic dissection and aortic aneurysms associated with 
fluoroquinolones: a systematic review and meta-analysis. Am J Med. 
2017;130(12):1449-1457 
14. Chien-Chang Lee, Meng-tse Gabriel Lee, Ronan Hsieh, Lorenzo Porta, Wan-
Chien Lee, Si-Huei Lee, Shy-Shin Chang. Oral Fluoroquinolone and the Risk of Aortic 
Dissection. J Am Coll Cardiol. 2018; 72 (12) 1369-1378. 
15. US Food and Drug Administration. Information for Healthcare Professionals: 
Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic 
ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), 
gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin 
(marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as 
Floxin)]. Available from: http://wayback.archive-
it.org/7993/20170112032310/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafe
tyInformationforPatientsandProviders/ucm126085.htm. Published July 8, 2008. 
Accessed November 23, 2019.  
16. US Food and Drug Administration. FDA Drug Safety Communication: FDA requires label 
changes to warn of risk for possibly permanent nerve damage from antibacterial 
fluoroquinolone drugs taken by mouth or by injection. http://wayback.archive-
it.org/7993/20170112031629/http:/www.fda.gov/Drugs/DrugSafety/ucm365050.htm. 
Published August 15, 2013. Accessed November 23, 2019.  
17. US Food and Drug Administration. FDA Drug Safety Communication: FDA updates 
warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. 
 
 31 
https://www.fda.gov/media/99425/download. Published July 26, 2016. Accessed 
September 22, 2019. 
18. US Food and Drug Administration. FDA Drug Safety Communication: FDA updates 
warning for fluoroquinolone antibiotics on risks of mental health and low blood sugar 
adverse reactions. https://www.fda.gov/news-events/press-announcements/fda-updates-
warnings-fluoroquinolone-antibiotics-risks-mental-health-and-low-blood-sugar-adverse. 
Published July 10, 2018.Accessed November 23, 2019. 
19. Almalki ZS, Yue Xiaomeng, Xia Y, Wigle PR, Guo JJ. Utilization, spending, and price 
trends for quinolones in the US Medicaid Program: 25 Years’ Experience 1991-2015. 
PharmacoEconomics-Open.2017;1(2):123-31.  
20. Linder JA, Huang ES, Steinman MA, Gonzales R, Stfford RS. Fluoroquinolone 
prescribing in the United States: 1995-2002. The American Journal of Medicine. 2005; 
118(3):259-268 
21. Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Danziger LH.  A national evaluation of 
antibiotic expenditures by healthcare settin in the United States, 2009. J Antimicrob 
Chemother. 2013; 68(3):715-718.  
22. Cohen A, Rabbani A, Shah N, Alexander GC. Changes in glitazone use among office-
based physicians in the U.S., 2003-2009. Diabetes Care. 2010;33(4):823–825. 
doi:10.2337/dc09-1834 
23. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC.  Ambulatory Treatment of 
Type 2 Diabetes in the U.S., 1997-2012. Diabetes Care. 2014;37:985-992.  
24. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 
1990 to 2002. J Am Coll Cardiol. 2003;41(1):56-61 
 
 32 
25. Joinpoint Regression Program, latest release version 4.7.0.0 Feb. 2019; Statistical 
Methodology and Applications Brach, Surveillance Research Program, National Cancer 
Institute. Available from: http://srab.cancer.gov/joinpoint/. Accessed January 27, 2020.  
26. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with 
applications to cancer rates. Statistics in Medicine. 2000; 19:335-351.  
27. Yarrington ME, Anderson DJ, Dodds Ashley E, Jones T, Davis A, Johnson M, Lokhny-
gina Y, Sexton DJ, Moehring RW. Impact of FDA black box warning on fluoroquinolone 
and alternative antibiotic use in southeastern US hospitals. Infect Control Hosp 
Epidemiol. 2019;40(11):1297-1300.  
28. N Gangan, K Strover, K Barber, E Pittman et al. Assessing the trends in the use of 
fluoroquinolones before and after FDA notice of its restricted use in uncomplicated 
infections. Value in Health-ISPOR 2018;21(1):S157.  
29. Willis Z, Dusetzina S, Anderson DJ, Pajewski N, Kinlaw A. 1863. Antibiotic Prescribing 
Before and After an FDA Boxed Warning on Fluoroquinolones in 2016. Open Forum 
Infect Dis. 2018;5(Suppl 1):S532. Published 2018 Nov 26. doi:10.1093/ofid/ofy210.1519 
30. Lin K, Zahlanie Y, Ortwine J, Mang N, Wei W, Prokesch BC. 2077. Fluoroquinolone 
Usage Reduction in the Outpatient Setting. Open Forum Infect Dis. 2019;6(Suppl 
2):S700. Published 2019 Oct 23. doi:10.1093/ofid/ofz360.1757 
31. Wong Beringer A, Nguyen LH, Lee M, Shriner KA, Pallares J. An antimicrobial 
stewardship program with a focus on reducing fluoroquinolone 
overuse. Pharmacotherapy. 2009;29(6):736–43. 10.1592/phco.29.6.736 
32. Buehrle D, Shively N, Wagener M, Calncy C, Decker BK. Sustained reductions in overall 
and unnecessary antibiotic prescribing at primary care clinics in a veterans affair 




33. Kabbani S, Hersh AL, Shapiro DJ, Fleming-Dutra KE, Pavia AT, Hicks LA. Opportunities 
to improve fluoroquinolone prescribing in the United States for adult ambulatory care 
visits. Clin Infect Dis. 2018 Jun 18;67(1):134-136 
34. Mang N, Wei W, Ortwine J, Prokesch B. 1842. Fluoroquinolone Usage Reduction in the 
Outpatient Setting. Open Forum Infect Dis. 2018;5(Suppl 1):S525–S526. Published 2018 
Nov 26. doi:10.1093/ofid/ofy210.1498 
35. Centers for Disease Control and Prevention. What do we know about antibiotic use in 
outpatient settings? Available from: https://www.cdc.gov/antibiotic-use/stewardship-
report/outpatient.html. Accessed November 29, 2019.  
36. E Charani, R Ahmad, T M Rawson, E Castro-Sanchèz, C Tarrant, A H Holmes. The 
Differences in Antibiotic Decision-making Between Acute Surgical and Acute Medical 
Teams: An Ethnographic Study of Culture and Team Dynamics. Clinical Infectious 
Diseases. 2019; 69(1):12-20. 
37. Martin S. Younger physicians, specialists use Internet more. CMAJ. 2004;170(12):1780. 
38. Choudhry NK, Fletcher RH, Soumerai SB. Systematic Review: The Relationship 
between Clinical Experience and Quality of Health Care. Ann Intern Med. 2005;142:260–
273. 
39. Sammer CE, Lykens K, Singh KP. Physician characteristics and the reported effect of 
evidence-based practice guidelines. Health Serv Res. 2008;43(2):569–581.  
40. Garritty C, El Emam K. Who's using PDAs? Estimates of PDA use by health care 













Dr. Siddhi Umarje, Pharm.D. 
Education 
PharmD, Bharati Vidyapeeth University, Pune, India, 2018 
ScM Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, 2020 
Overview 
Siddhi Umarje is a graduate student at the Johns Hopkins Bloomberg School of Public Health. 
Siddhi received her Pharm.D. and completed clinical pharmacy residency at Bharati Hospital 
and Research Center in 2018.She has two years of clinical experience and one year of research 
experience in India. She is pursuing formal research training in epidemiology, focusing on 
clinical & cardiovascular epidemiology research, and pharmacoepidemiology research. She is a 
Center Scholar at the Center for Drug Safety and Effectiveness and a part-time Research 
Assistant in the Department of Epidemiology at Johns Hopkins School of Public Health. In 2019, 
she worked as a pre-doctoral research fellow at the Division of Pharmacoepidemiology and 
Pharmacoeconomics, Brigham & Women’s Hospital and Harvard Medical School, Boston. Her 
research interests include drug safety, comparative effectiveness, drug utilization, and 
pharmacovigilance.  
 
 
 
 
 
 
 
 
 
